<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Report</title>
	<atom:link href="http://www.tapanray.in/tag/report/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Regulatory Failures Are Still Risking Patient Lives</title>
		<link>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=regulatory-failures-are-still-risking-patient-lives</link>
		<comments>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/#comments</comments>
		<pubDate>Sun, 06 Oct 2024 06:37:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[failures]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Leverage]]></category>
		<category><![CDATA[lives]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[risking]]></category>
		<category><![CDATA[self-regulation]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[substandard]]></category>
		<category><![CDATA[sustainabilitycompanies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TechnologyAwareness]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10880</guid>
		<description><![CDATA[India&#8217;s pharmaceutical industry faces renewed scrutiny as the Drug Controller General of India (DCGI) flagged numerous substandard drugs in September 2024. At the same time, an October 02, 2024, Business Standard report highlights an ongoing crackdown on such drugs by regulators. This article explores &#8230; <a href="http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/regulatory-failures-are-still-risking-patient-lives/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why MNC Pharma Still Moans Over Indian IP Ecosystem?</title>
		<link>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-mnc-pharma-still-moans-over-indian-ip-ecosystem</link>
		<comments>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/#comments</comments>
		<pubDate>Mon, 14 May 2018 00:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2018]]></category>
		<category><![CDATA[3.d]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[Chamber]]></category>
		<category><![CDATA[Cheaper]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[concerns]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[Form 27]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Moon]]></category>
		<category><![CDATA[multi]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[TADF]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UN]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USTR]]></category>
		<category><![CDATA[working]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9004</guid>
		<description><![CDATA[Improving patient access to expensive drugs, paving the way for entry of their cheaper generic equivalents, post patent expiry, and avoiding evergreening, is assuming priority a priority focus area in many countries. The United States is no exception, in this &#8230; <a href="http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Price Negotiation For Patented Drugs: Still Continues A Policy Paralysis</title>
		<link>http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=price-negotiation-for-patented-drugs-continues-a-policy-paralysis</link>
		<comments>http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/#comments</comments>
		<pubDate>Mon, 12 Dec 2016 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interministerial]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[policy Paralysis]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8006</guid>
		<description><![CDATA[Many poor and even middle-income patients, who spend their entire life savings for treatment of life-threatening ailments, such as, cancer, have been virtually priced out of the access to patented new drugs, across the world. As articulated by the American &#8230; <a href="http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/price-negotiation-for-patented-drugs-continues-a-policy-paralysis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Recent Ban On Irrational FDCs: History Repeats Itself</title>
		<link>http://www.tapanray.in/the-recent-ban-on-irrational-fdcs-history-repeats-itself/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-recent-ban-on-irrational-fdcs-history-repeats-itself</link>
		<comments>http://www.tapanray.in/the-recent-ban-on-irrational-fdcs-history-repeats-itself/#comments</comments>
		<pubDate>Mon, 21 Mar 2016 00:00:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[294]]></category>
		<category><![CDATA[344]]></category>
		<category><![CDATA[59th]]></category>
		<category><![CDATA[ADE]]></category>
		<category><![CDATA[ADR]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Combination]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Corex]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[Dose]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[evidence]]></category>
		<category><![CDATA[FDCs]]></category>
		<category><![CDATA[Fixed]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[history]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[injunction]]></category>
		<category><![CDATA[interim]]></category>
		<category><![CDATA[irrational]]></category>
		<category><![CDATA[itself]]></category>
		<category><![CDATA[Kokate]]></category>
		<category><![CDATA[madras]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[repeats]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Sri Lanka]]></category>
		<category><![CDATA[stay]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7543</guid>
		<description><![CDATA[The recent regulatory ban on a large number of irrational Fixed Dose Combination (FDC) drugs is not a new incident in India. A similar mega ban was announced even before, about nine years ago. Intriguingly, the saga continues, for various &#8230; <a href="http://www.tapanray.in/the-recent-ban-on-irrational-fdcs-history-repeats-itself/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-recent-ban-on-irrational-fdcs-history-repeats-itself/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>For Drug Safety Concern: “Whistleblower’s Intention Should Be Nationalistic”</title>
		<link>http://www.tapanray.in/for-drug-safety-concern-whistleblowers-intention-should-be-nationalistic/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=for-drug-safety-concern-whistleblowers-intention-should-be-nationalistic</link>
		<comments>http://www.tapanray.in/for-drug-safety-concern-whistleblowers-intention-should-be-nationalistic/#comments</comments>
		<pubDate>Mon, 14 Mar 2016 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[Anti-nationalistic]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[CDA]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Dinesh]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thakur]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Whistleblower]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7529</guid>
		<description><![CDATA[In the recent weeks, three significant developments related to the Pharmaceutical Industry in India, have triggered rejuvenated concerns in the following critical areas:  A. Overall drug safety standards in the country B.  Self serving interest, rather than patients’ interest, dominate &#8230; <a href="http://www.tapanray.in/for-drug-safety-concern-whistleblowers-intention-should-be-nationalistic/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/for-drug-safety-concern-whistleblowers-intention-should-be-nationalistic/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Healthcare In India (2016-17): Whither Goest Thou?</title>
		<link>http://www.tapanray.in/healthcare-in-india-2016-17-whither-goest-thou/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=healthcare-in-india-2016-17-whither-goest-thou</link>
		<comments>http://www.tapanray.in/healthcare-in-india-2016-17-whither-goest-thou/#comments</comments>
		<pubDate>Mon, 29 Feb 2016 00:00:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2015-16]]></category>
		<category><![CDATA[2016-17]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[cess]]></category>
		<category><![CDATA[economic]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[Goest]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[My]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Survey]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thou]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[Whither]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7497</guid>
		<description><![CDATA[The Union Budget 2016-17 will be proposed today by the Finance Minister before the Indian Parliament. As many critical questions are currently being raised about the real health of the Indian economy, across the globe, the Union Finance Minister shoulders &#8230; <a href="http://www.tapanray.in/healthcare-in-india-2016-17-whither-goest-thou/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/healthcare-in-india-2016-17-whither-goest-thou/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Against Pharma Marketing Malpractices: A Gutsy Step</title>
		<link>http://www.tapanray.in/against-pharma-marketing-malpractices-a-gutsy-step/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=against-pharma-marketing-malpractices-a-gutsy-step</link>
		<comments>http://www.tapanray.in/against-pharma-marketing-malpractices-a-gutsy-step/#comments</comments>
		<pubDate>Mon, 22 Feb 2016 00:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[58th]]></category>
		<category><![CDATA[BBC]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Clinton]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[conflit]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[dollars for doc]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[follow]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Gutsy]]></category>
		<category><![CDATA[Hilary]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[pharnaceuticals]]></category>
		<category><![CDATA[Physician Payments Sunshine Act]]></category>
		<category><![CDATA[ProPublica]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7447</guid>
		<description><![CDATA[January 7, 2016 edition of ‘The Financial Times (FT)’ reported that responding to escalating pressure on the drug industry, related to its ‘Conflict of Interest’ with the doctors and other related professionals, GlaxoSmithKline (GSK) has decided taking a very unorthodox &#8230; <a href="http://www.tapanray.in/against-pharma-marketing-malpractices-a-gutsy-step/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/against-pharma-marketing-malpractices-a-gutsy-step/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biosimilar Drugs: Why Prescriptions Aren’t Still Enough?</title>
		<link>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biosimilar-drugs-why-prescriptions-arent-still-enough</link>
		<comments>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/#comments</comments>
		<pubDate>Mon, 14 Sep 2015 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[filgrastim]]></category>
		<category><![CDATA[filgrastim-sndz]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Hatch-Waxman]]></category>
		<category><![CDATA[immunogenicity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Interchangeability]]></category>
		<category><![CDATA[M&M]]></category>
		<category><![CDATA[marketsandmarkets]]></category>
		<category><![CDATA[Neupogen]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[QuantiaMD]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Sandoz]]></category>
		<category><![CDATA[Similar]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Zarxio]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7055</guid>
		<description><![CDATA[On September 3, 2015, in a Press Release, Novartis announced, “Zarxio(TM) (filgrastim-sndz) is now available in the United States. Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA) and the first to launch in the &#8230; <a href="http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biosimilar-drugs-why-prescriptions-arent-still-enough/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Fake Drugs Kill More People Each Year Than Terrorism In The Last 40 years&#8217;</title>
		<link>http://www.tapanray.in/fake-drugs-kill-more-people-each-year-than-terrorism-in-the-last-40-years/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fake-drugs-kill-more-people-each-year-than-terrorism-in-the-last-40-years</link>
		<comments>http://www.tapanray.in/fake-drugs-kill-more-people-each-year-than-terrorism-in-the-last-40-years/#comments</comments>
		<pubDate>Mon, 29 Jun 2015 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2009]]></category>
		<category><![CDATA[Anil]]></category>
		<category><![CDATA[ASSOCHAM]]></category>
		<category><![CDATA[CBI]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Director]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[FICCI]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[INTERPOL]]></category>
		<category><![CDATA[kill]]></category>
		<category><![CDATA[Ostrich Syndrome]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Sinha]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[substandard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[terrorism]]></category>
		<category><![CDATA[Wolf in sheep's clothing]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6767</guid>
		<description><![CDATA[In this article, I shall deliberate on ‘fake medicines’ that we may at times land up into buying, without any inkling that instead of curing or managing the ailments, these products can push us into serious health hazards, quite contrary &#8230; <a href="http://www.tapanray.in/fake-drugs-kill-more-people-each-year-than-terrorism-in-the-last-40-years/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/fake-drugs-kill-more-people-each-year-than-terrorism-in-the-last-40-years/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>With Highest Billionaire Wealth Concentration, India Tops Malnutrition Chart in South Asia: &#8220;What Future Do You Want?&#8221;</title>
		<link>http://www.tapanray.in/with-highest-billionaire-wealth-concentration-india-tops-malnutrition-chart-in-south-asia-what-future-do-you-want/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=with-highest-billionaire-wealth-concentration-india-tops-malnutrition-chart-in-south-asia-what-future-do-you-want</link>
		<comments>http://www.tapanray.in/with-highest-billionaire-wealth-concentration-india-tops-malnutrition-chart-in-south-asia-what-future-do-you-want/#comments</comments>
		<pubDate>Mon, 26 Jan 2015 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Amit]]></category>
		<category><![CDATA[Asia]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[Billionaire]]></category>
		<category><![CDATA[BJP]]></category>
		<category><![CDATA[Chart]]></category>
		<category><![CDATA[Concentration]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Davos]]></category>
		<category><![CDATA[demographic]]></category>
		<category><![CDATA[dividend]]></category>
		<category><![CDATA[Gates]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[highest]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inequality]]></category>
		<category><![CDATA[Justice Louis Brandeis]]></category>
		<category><![CDATA[Malnutrition]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[oxfam]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Shah]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[South]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tops]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[UNICEF]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Wealth]]></category>
		<category><![CDATA[WEF]]></category>
		<category><![CDATA[What Future Do You Want]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6352</guid>
		<description><![CDATA[Two recent global research reports, though on different spheres, place India at the top of the respective blocks. However, the take away messages that the studies offer are indeed poles apart in qualitative terms and worth pondering over collectively. On &#8230; <a href="http://www.tapanray.in/with-highest-billionaire-wealth-concentration-india-tops-malnutrition-chart-in-south-asia-what-future-do-you-want/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/with-highest-billionaire-wealth-concentration-india-tops-malnutrition-chart-in-south-asia-what-future-do-you-want/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
